134 related articles for article (PubMed ID: 9817400)
41. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.
Chang JI; Bucci J
J Med Case Rep; 2016 Nov; 10(1):323. PubMed ID: 27836000
[TBL] [Abstract][Full Text] [Related]
42. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
[TBL] [Abstract][Full Text] [Related]
43. Adenocarcinoma of the prostate metastatic to the choroid of the eye.
Keizur JJ; Kane CJ; North R; Leidich RB
Prostate; 1995 Dec; 27(6):336-9. PubMed ID: 7501546
[TBL] [Abstract][Full Text] [Related]
44. Combination treatment versus LHRH alone in advanced prostatic cancer.
Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
[TBL] [Abstract][Full Text] [Related]
45. Significant financial differences of chemical and surgical androgen deprivation in a contemporary cohort.
Paul CJ; Garje R; Kreder KJ; Mott SL; Gellhaus PT
Transl Androl Urol; 2022 Sep; 11(9):1252-1261. PubMed ID: 36217391
[TBL] [Abstract][Full Text] [Related]
46. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.
Civantos F; Marcial MA; Banks ER; Ho CK; Speights VO; Drew PA; Murphy WM; Soloway MS
Cancer; 1995 Apr; 75(7):1634-41. PubMed ID: 8826921
[TBL] [Abstract][Full Text] [Related]
47. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
48. [A posteriori biological demonstration of the concept of hormone-radiotherapy combination in cancer of the prostate].
Magné N
Bull Cancer; 2013 May; 100(5):415-6. PubMed ID: 23862197
[No Abstract] [Full Text] [Related]
49. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
[TBL] [Abstract][Full Text] [Related]
50. Non-castrate metastatic prostate cancer: have the treatment options changed?
Palmbos PL; Hussain M
Semin Oncol; 2013 Jun; 40(3):337-46. PubMed ID: 23806498
[TBL] [Abstract][Full Text] [Related]
51. Medicare reimbursement and prescribing hormone therapy for prostate cancer.
Keating NL
J Natl Cancer Inst; 2010 Dec; 102(24):1814-5. PubMed ID: 21131579
[No Abstract] [Full Text] [Related]
52. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.
Østergren PB; Kistorp C; Fode M; Henderson J; Bennedbæk FN; Faber J; Sønksen J
J Urol; 2017 Jun; 197(6):1441-1447. PubMed ID: 27939836
[TBL] [Abstract][Full Text] [Related]
53. Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
Doyle-Lindrud S
Clin J Oncol Nurs; 2006 Oct; 10(5):565-6. PubMed ID: 17063610
[TBL] [Abstract][Full Text] [Related]
54. Implantable LHRH agonist for treatment of prostate cancer.
Lajiness MJ
Urol Nurs; 2006 Oct; 26(5):408, 414. PubMed ID: 17078331
[No Abstract] [Full Text] [Related]
55. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
[TBL] [Abstract][Full Text] [Related]
56. The comparative evaluation of apoptosis produced by leuprolide or orchiectomy on rat prostate tissue.
Cakiroglu B; Hazar AI; Eyyupoglu SE; Can Balci MB; Sinanoglu O; Tuzlali P
Arch Ital Urol Androl; 2016 Jan; 87(4):265-9. PubMed ID: 26766795
[TBL] [Abstract][Full Text] [Related]
57. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
Mizusawa H; Kontani K; Okaneya T; Yoneyama T
Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
[TBL] [Abstract][Full Text] [Related]
58. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
Abbou CC; Lucas C; Leblanc V
Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
[TBL] [Abstract][Full Text] [Related]
59. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
[TBL] [Abstract][Full Text] [Related]
60. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer.
Yri OE; Bjoro T; Fossa SD
Eur Urol; 2006 Jan; 49(1):54-8; discussion 58. PubMed ID: 16314038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
